Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

ludc webb

Harry Björkbacka

Researcher

ludc webb

Circulating GDF-15 levels predict future secondary manifestations of cardiovascular disease explicitly in women but not men with atherosclerosis

Author

  • Aisha Gohar
  • Isabel Gonçalves
  • Joyce Vrijenhoek
  • Saskia Haitjema
  • Ian van Koeverden
  • Jan Nilsson
  • Gert J. de Borst
  • Jean-Paul P. M. de Vries
  • Gerard Pasterkamp
  • Hester M den Ruijter
  • Harry Björkbacka
  • Saskia C A de Jager

Summary, in English

Background: Elevated serum levels of growth differentiation factor-15 (GDF-15), is an established risk factor for a range of cardiovascular diseases.We aimed to evaluate the predictive value of plasma GDF-15 as a biomarker for secondary cardiovascular events (CVE) in patients with atherosclerosis undergoing carotid endarterectomy (CEA). Secondly, we determined whether plasma GDF-15 was associated with carotid plaque characteristics. Methods: Circulating GDF-15 levels were determined by Luminex assay in a cohort of 1056 patients from the Athero-Express biobank. Composite endpoint was defined as major CVE, death and peripheral vascular interventions. Findings were validated in 473 patients from the independent Carotid Plaque Imaging Project biobank. Results: GDF-15 levels did not associate with secondary CVE in the total cohort. However, following a significant interaction with sex, it was found to be strongly, independently predictive of secondary CVE in women but not men (quartile 4 vs. quartile 1: HR 3.04 [95% CI 1.35-6.86], p = 0.007 in women vs. HR 0.96 [95% CI 0.66-1.40], p = 0.845 in men). This was also observed in the validation cohort (women: HR 2.28 [95% CI 1.04-5.05], p = 0.041), albeit dependent upon renal function. In addition, GDF-15 was associated with the presence of plaque smooth muscle cells and calcification. Conclusion: High circulating GDF-15 levels are predictive of secondary CVE in women but not in men with carotid atherosclerotic disease undergoing CEA, suggesting a potential use for GDF-15 as a biomarker for secondary prevention in women. Sex differences in the role of GDF-15 in atherosclerotic disease deserve further interest.

Department/s

  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Cellular Metabolism and Inflammation
  • EpiHealth: Epidemiology for Health

Publishing year

2017-03-22

Language

English

Pages

430-436

Publication/Series

International Journal of Cardiology

Volume

241

Document type

Journal article

Publisher

Elsevier

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • Atherosclerosis
  • Biomarker
  • GDF-15
  • Prognosis
  • Secondary outcome
  • Women

Status

Published

Research group

  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Cellular Metabolism and Inflammation

ISBN/ISSN/Other

  • ISSN: 0167-5273